ID | 1172 |
Name of the vaccine | rBV A/B |
Microbe | Bacteria |
Disease name | Botulism |
Name of bacteria | Clostridium botulinum |
Type of vaccine | Recombinant |
Nucleic acid content | DNA |
Age | 18 to 55 years |
Description of the vaccine | Recombinant Botulinum vaccine A/B. |
Name of the manufacturer | DynPort Vaccine Company LLC, A GDIT Company |
Name of the manufacturing country | NA |
Year of manufacture | 2019 |
Clinical Phase status | Clinical - Withdrawn |
Bacterial strain | Gram-positive anaerobic bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | 0.5 mL dose at Days 0, 28 and 182. |
Mechanism of action | BoNT neutralizing antibodies bind to BoNT and prevent its action at the cholinergic neurons. |
Route of administration | Intramuscular |
Indications | Protects from BoNT serotype A, subtype A1 (BoNT/A1) and BoNT serotype B, subtype B1 (BoNT/B1). |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Transient mild inflammation at the injection site. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 22269871 |
Clinical trial number | NCT01940315 |
Reference | NA |
Other name | NA |
Additional Links | NA
|